Racial variation in the cost-effectiveness of chemotherapy for prostate cancer

Journal of Oncology Practice

Volumn 7, Issue 3 SUPPL., 2011, Pages

  Grabner, Michael ^a,b   Onukwugha, Eberechukwu ^a,b   Jain, Rahul ^a,b   Mullins, C Daniel ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MITOXANTRONE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CAUCASIAN; CLINICAL EXAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ETHNIC OR RACIAL ASPECTS; EVIDENCE BASED PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; METASTASIS; NEGRO; OBSERVATIONAL STUDY; PROSTATE CANCER; RACE DIFFERENCE; REIMBURSEMENT; RETROSPECTIVE STUDY; SAMPLE; SENSITIVITY ANALYSIS; SURVIVAL TIME;

EID: 80052730007     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000294     Document Type: Article

References (36)

1. Kravitz RL, Duan N, Braslow J: Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82:661-687, 2004 (Pubitemid 40143102)
2. Gabler NB, Duan N, Liao D, et al: Dealing with heterogeneity of treatment effects: Is the literature up to the challenge? Trials 10:43, 2009
3. Sculpher M: Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 26:799-806, 2008
4. Stevens W, Normand C: Optimisation versus certainty: Understanding the issue of heterogeneity in economic evaluation. Soc Sci Med 58:315-320, 2004 (Pubitemid 37353044)
5. American Cancer Society: Cancer Facts & Figures 2010. Atlanta, GA, American Cancer Society, 2010. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-026238.pdf
6. Mullins CD, Onukwugha E, Bikov K, et al: Health disparities in staging of SEER-Medicare prostate cancer patients in the United States. Urology 76:566-572, 2010
7. Gilligan T, Wang PS, Levin R, et al: Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 164:1858-1864, 2004 (Pubitemid 39274355)
8. Zeliadt SB, Potosky AL, Etzioni R, et al: Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64:1171-1176, 2004 (Pubitemid 39647061)
9. Do YK, Carpenter WR, Spain P, et al: Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control 21:31-40, 2010
10. Powell IJ: Epidemiology and pathophysiology of prostate cancer in African- American men. J Urol 177:444-449, 2007
11. Sternberg CN: Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 43:105-121, 2002
12. Dagher R, Li N, Abraham S, et al: Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147-8151, 2004 (Pubitemid 40053372)
13. Lassi K, Dawson NA: Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22:263-267, 2010
14. Michael A, Syrigos K, Pandha H: Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 12:13-16, 2009
15. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
16. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002
17. Brown ML, Riley GF, Schussler N, et al: Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40:IV-104-117, 2002 (suppl)
18. Desgagné A, Castilloux AM, Angers JF, LeLorier J: The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 13:487-497, 1998
19. Doshi JA, Glick HA, Polsky D: Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health 9:334-340, 2006 (Pubitemid 44337786)
20. Bang H, Tsiatis AA: Estimating medical costs with censored data. Biometrika 87:329-343, 2000
21. Zhao H, Wang H: Cost and cost-effectiveness analysis with censored data, in Faries D, Leon A, Haro J, et al (ed): Analysis of Observational Health Care Data Using SAS. Cary, NC, SAS Institute, 2010
22. Chaudhary MA, Stearns SC: Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Stat Med 15:1447-1458, 1996 (Pubitemid 26242553)
23. Briggs AH, O'Brien BJ, Blackhouse G: Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 23:377-401, 2002 (Pubitemid 34508080)
24. Rosenbaum P, Rubin D: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
25. Parsons LS: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Presented at the 26th Annual SAS Users' Group International Conference. Long Beach, CA, April 22-25, 2001 (abstr 214-26)
26. Keppel K, Garcia T, Hallquist S, et al: Comparing racial and ethnic populations based on Healthy People 2010 objectives. Healthy People Stat Notes 2008:1-16, 2008
27. Mullins CD, Onukwugha E, Cooke JL, et al: The potential impact of comparative effectiveness research on the health of minority populations. Health Aff (Millwood) 29:2098-2104, 2010
28. Bruner DW, Jones M, Buchanan D, et al: Reducing cancer disparities for minorities: A multidisciplinary research agenda to improve patient access to health systems, clinical trials, and effective cancer therapy. J Clin Oncol 24:2209-2215, 2006 (Pubitemid 46630694)
29. Ford JG, Howerton MW, Lai GY, et al: Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer 112:228-242, 2008
30. Cook DI, Gebski VJ, Keech AC: Subgroup analysis in clinical trials. Med J Aust 180:289-291, 2004 (Pubitemid 38372234)
31. Kent DM, Rothwell PM, Ioannidis JP, et al: Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. Trials 11:85, 2010
32. Collins R, Fenwick E, Trowman R, et al: A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 11:iii-iv, xv-xviii, 1-179, 2007
33. Ramsey S, Willke R, Briggs A, et al: Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report. Value Health 8:521-533, 2005 (Pubitemid 41727304)
34. Johnson ML, Crown W, Martin BC, et al: Good research practices for comparative effectiveness research: Analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources - The ISPOR Good Research Practices for Retrospective Database Analysis Task Force report, part III. Value Health 12:1062-1073, 2009
35. Willan AR, Lin DY, Manca A: Regression methods for cost-effectiveness analysis with censored data. Stat Med 24:131-145, 2005 (Pubitemid 40074070)
36. Basu A, Manning WG: Estimating lifetime or episode-of-illness costs under censoring. Health Econ 19:1010-1028, 2010